As a company built on delivering positive health outcomes, sustainability
underpins everything we do. As we strive to reach more and more patients by
2025, we are evolving our approach and developing a roadmap that will further
embed sustainability into our DNA. This will ensure we effectively address the
most fundamental issues for our business and for society.
Our sustainability framework demonstrates our
commitment to operating responsibly, working with
integrity and delivering sustainable growth. In 2015,
the DU Laboratories Limited Board endorsed an initiative to
pursue a clear and prioritised sustainability framework
that is closely aligned to the company’s overall
Our sustainability priorities were initially set in 2013. In late 2015, we initiated a refreshed materiality assessment that includes input from internal and external stakeholders. We are using the assessment to refine our priorities further and confirm our strategy, as we develop a roadmap towards further embedding sustainability into the DNA of our company.
We believe our long-term success lies in making better, deeper connections with our stakeholders, understanding their worlds and combining forces to achieve common goals. To earn society’s trust, we must speak but also listen. The feedback we receive from stakeholders, through both the materiality process and ongoing stakeholder dialogue, informs our sustainability approach, commitments and actions. We define a stakeholder as any individual or group who can affect, or is affected by, our business.
We carry out regular formal and informal engagement with stakeholders through a wide range of channels – from digital to face-to-face dialogue – to understand their views and concerns. Through a multi-stakeholder engagement approach, we identify systematic activities to create opportunities for interaction with groups of our stakeholders. We continue to use feedback from our various stakeholder dialogues to make sure that appropriate considerations are being included in our strategy development and risk management planning. All our relationships and engagement, including with patient groups and other healthcare organisations, are based on transparent and shared objectives to improve the lives of patients.
Patient groups are independent organisations that provide advice and support to patients and their families and other caregivers. Staying in touch with their changing needs is vital to our aim of making the most meaningful difference we can to patient health. We continually talk to patient groups, organisations and physicians to understand what they need and want.
We partner with other organisations to promote access to the best science, and to stimulate
innovation for the delivery of new, life-changing medicines. We are always looking for
business development opportunities that support our vision and help deliver our business
Ensuring these partnerships are transparent and uphold our high ethical standards is vital
to our reputation. When making new acquisitions and developing partnership opportunities,
sustainability is integral to our due diligence process.
We also consider ethical conduct in sales and marketing, safety, environmental management
and other sustainability issues – including the historical liabilities of potential partners
and the practices they currently have in place. This way, we ensure that we only take
forward the most attractive and sustainable opportunities.